YOLFTbeta
11

Qurient Co. Ltd

115180 · KQ · Healthcare / Biotechnology

14,510.00KRW-1930.00 (-11.74%)

Price History

Full chart

Market Stats

Previous Close16,440.00
Open16,200.00
Day Range14,450.00 – 16,800.00
52-Week Range14,330.00 – 62,900.00
Volume246.04K
Market Cap919.45B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.46
50-Day Avg22,114.80
200-Day Avg29,050.10

About

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors. The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is headquartered in Seongnam-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Ki-Yean Nam
  • Employees31
  • HeadquartersC-dong 801, Seongnam-si, South Korea, 13487, Korea
  • Websitehttps://www.qurient.com

Leadership

  • Dr. Ki-Yean NamCEO, CSO & Chairman · b. 1971
  • Mr. Chang Eyun YuChief Financial Officer
  • Dr. Kim Jae-SeungChief Technology Officer · b. 1968
  • Ms. Hyunjin LimSenior Vice President of Management Administration Officer
  • Dr. Joongsik HwangDirector
  • Dr. Seung-Joo LeeCSO

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue215.28M0000--4.89B8.47B9.03B9.18B6.98B
Growth (%)--100.00%------+73.33%+6.65%+1.64%-23.94%
Cost of Revenue00000--4.00B6.69B7.27B7.83B6.05B
Gross Profit215.28M0000--885.22M1.78B1.76B1.35B929.87M
Gross Margin100.00%------18.12%21.04%19.52%14.71%13.32%
Operating Expense6.86B8.23B11.08B12.72B16.69B--25.13B29.26B24.98B28.83B30.69B
Operating Income-6.65B-8.23B-11.08B-12.72B-16.69B-23.17B-21.02B-24.24B-27.47B-23.21B-27.48B-29.76B
Operating Margin-3087.06%-------496.18%-324.43%-257.02%-299.33%-426.16%
EBITDA---------26.38B-21.41B-24.10B-29.99B
EBITDA Margin---------311.45%-237.07%-262.58%-429.50%
Net Income-10.71B-9.30B-10.54B-12.20B-16.42B-22.70B-20.50B-22.85B-25.46B-21.12B-23.57B-30.05B
Net Income Margin-4973.15%-------467.63%-300.61%-233.80%-256.73%-430.41%
R&D4.33B4.63B6.05B7.58B12.55B--16.44B19.69B16.76B20.43B21.52B
R&D as % of Total Revenue2012.01%------336.44%232.47%185.62%222.60%308.16%
Interest Expense000000036.59M25.96M18.60M27.78M310.52M
Interest Expense % of Total Revenue0.00%------0.75%0.31%0.21%0.30%4.45%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets11.43B3.86B26.24B15.68B43.20B20.51B60.81B57.62B38.41B52.50B65.57B61.99B
Total Liabilities33.11B963.76M1.89B1.15B3.79B3.14B4.24B3.55B3.28B5.88B7.97B22.80B
Total Equity-21.68B2.89B24.35B14.53B39.41B17.38B56.57B51.59B30.95B46.62B57.60B34.04B
Cash10.82B3.30B1.42B300-81012057018.47B20.60B1.94B1.85B21.04B
Total Debt-----460.89M755.83M-----

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.64B-7.54B-9.90B-12.59B-13.80B-24.00B-19.85B-24.37B-25.00B-21.97B-23.32B-28.67B
Investing Cash Flow709.29M5.90M-1.58B-7.54B-25.08B20.38B-39.08B-21.04B4.15B-24.10B-
Financing Cash Flow15.48B-1.39M31.82B1.54B41.18B-6.39M59.87B-6.27B31.55B26.78B-
Capital Expenditure281.01M87.87M50.29M72.78M432.10M12.51M10.67M259.76M518.62M101.08M83.74M3.70B
Free Cash Flow--------24.63B-25.52B-22.07B-23.40B-32.37B
Dividends Paid----------70.00M69.41M
FCF to OCF-------101.07%102.07%100.46%100.36%112.89%
Dividend Paid to FCF-----------0.30%-0.21%

Earnings

Report DateMar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Feb 1, 2019May 15, 2019Aug 14, 2019Nov 13, 2019Feb 11, 2020Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020May 14, 2021Aug 17, 2021Nov 15, 2021Dec 31, 2021May 16, 2022Aug 16, 2022Nov 14, 2022Mar 17, 2023Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Nov 7, 2024Dec 31, 2024May 12, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------------
EPS Actual-450.36-284.60-199.11-246.16-217.90-249.00-276.89-340.36-226.13-336.21-400.02-655.00-565.00-394.41-317.67-702.04-279.50-344.88-343.65-391.55-347.87-403.03-300.69-258.49-238.04-379.76-840.60-298.24-329.60-294.43-234.30-148.08-182.64-228.16-161.08-178.18-184.15-178.64-183.57-333.45-204.14-339.93
Surprise------------------------------------------
Timing-----------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours----After-hoursAfter-hoursAfter-hours-After-hoursPre-marketAfter-hoursAfter-hours------After-hours-After-hours-----

Key Statistics & Ratios

Market Cap919.45B
Enterprise Value826.49B
Trailing P/E0.00
Forward P/E0.00
Price / Sales130.10
Price / Book49.95
Revenue (TTM)7.07B
Gross Profit (TTM)815.58M
EBITDA-35.71B
Profit Margin0.00%
Operating Margin-672.86%
Return on Equity-102.04%
Return on Assets-43.48%
Shares Outstanding37.53M
Shares Float27.65M
Beta0.46
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Dec 18, 202313:10
  • Nov 9, 20231345:1161